Urolithiasis In a cardiovascular outcomes trial, 1.2% of WEGOVY-treated patients and 0.8% of patients receiving placebo reported urolithiasis, including serious reactions that were reported more frequently among patients receiving WEGOVY (0.6%) than placebo (0.4%)
Metabolite identification was confirmed by comparing the mass-to-charge ratio (m/z) and retention time with reference standards
Additionally, metabolic profiling has revealed that suppression of GLS1 induces a compensatory anaplerotic mechanism via pyruvate carboxylase (PC), which allows the release of a glutamine-independent supply of TCA intermediates by catalyzing the transformation of pyruvate to oxaloacetate 153
Its been a life-changing boost to my overall wellness! Chris A
You may want to stay on a lower dose if higher doses give you side effects, or you are happy with your weight loss without a dose increase
Understanding your individual metabolic response and genetic factors before treatment begins helps inform safer discontinuation planning